Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia

被引：50

作者：

Goulden, N

Bader, P

Van der Velden, V

Moppett, J

Schilham, M

Masden, HO

Krejci, O

Kreyenberg, H

Lankester, A

Révész, T

Klingebiel, T

Van Dongen, J

机构：

[1] Bristol Royal Hosp Sick Children, Dept Paediat Haematol & Oncol, Bristol BS2 8BJ, Avon, England

[2] Univ Kinderklin, Tubingen, Germany

[3] Univ Med Ctr Rotterdam, Erasmus MC, Leiden, Netherlands

[4] Leiden Univ, Med Ctr, Leiden, Netherlands

[5] Rigshosp, DK-2100 Copenhagen, Denmark

[6] Univ Hosp Motol, Prague, Czech Republic

[7] Univ Med Ctr, Utrecht, Netherlands

[8] Goethe Univ Frankfurt, D-6000 Frankfurt, Germany

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2003年 / 122卷 / 01期

关键词：

MRD; BMT; childhood ALL; relapse; Ig/TCR gene rearrangement PCR;

D O I：

10.1046/j.1365-2141.2003.04394.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Allogeneic stem cell transplantation (SCT) is a highly effective therapy for childhood acute lymphoblastic leukaemia (ALL). Concerns about unnecessary toxicity and expense mean that SCT is currently largely reserved for children who cannot be cured with chemotherapy. Not surprisingly, many such children also fail SCT. Retrospective studies have shown that a single analysis of minimal residual disease (MRD) pre-SCT identified those at highest risk of relapse. It is now appropriate to call for the universal incorporation of standardized MRD testing into SCT protocols as the next step to maximize the clinical impact of this technology in ALL.

引用

收藏

页码：24 / 29

页数：6

相关论文

共 19 条

[1] Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL [J].

Bader, P ;

Hancock, J ;

Kreyenberg, H ;

Goulden, NJ ;

Niethammer, D ;

Oakhill, A ;

Steward, CG ;

Handgretinger, R ;

Beck, JF ;

Klingebiel, T .

LEUKEMIA, 2002, 16 (09) :1668-1672

[2] Allogeneic bone marrow transplantation for a subset of children with acute lymphoblastic leukemia in third remission: a conceivable alternative? [J].

Borgmann, A ;

Baumgarten, E ;

Schmid, H ;

Dopfer, R ;

Ebell, W ;

Gobel, U ;

Niethammer, D ;

Gadner, H ;

Henze, G .

BONE MARROW TRANSPLANTATION, 1997, 20 (11) :939-944

[3] Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia [J].

Cavé, H ;

ten Bosch, JV ;

Suciu, S ;

Guidal, C ;

Waterkeyn, C ;

Otten, J ;

Bakkus, M ;

Thielemans, K ;

Grandchamp, B ;

Vilmer, E .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :591-598

[4]

Chessells JM, 2000, BRIT J HAEMATOL, V108, P204

[5] Relapsed lymphoblastic leukaemia in children: A continuing challenge [J].

Chessells, JM .

BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (02) :423-438

[6] Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia [J].

Eckert, C ;

Biondi, A ;

Seeger, K ;

Cazzaniga, G ;

Hartmann, R ;

Beyermann, B ;

Pogodda, M ;

Proba, J ;

Henze, G .

LANCET, 2001, 358 (9289) :1239-1241

[7] Megadose transplantation of purified peripheral blood CD34+progenitor cells from HLA-mismatched parental donors in children [J].

Handgretinger, R ;

Klingebiel, T ;

Lang, P ;

Schumm, M ;

Neu, S ;

Geiselhart, A ;

Bader, P ;

Schlegel, PG ;

Greil, J ;

Stachel, D ;

Herzog, RJ ;

Niethammer, D .

BONE MARROW TRANSPLANTATION, 2001, 27 (08) :777-783

[8] Haemopoietic stem cell transplantation from unrelated donors [J].

Heslop, HE .

BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (01) :2-6

[9] Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia [J].

Knechtli, CJC ;

Goulden, NJ ;

Hancock, JP ;

Grandage, VLG ;

Harris, EL ;

Garland, RJ ;

Jones, CG ;

Rowbottom, AW ;

Hunt, LP ;

Green, AF ;

Clarke, E ;

Lankester, AW ;

Cornish, JM ;

Pamphilon, DH ;

Steward, CG ;

Oakhill, A .

BLOOD, 1998, 92 (11) :4072-4079

[10]

Moppett JP, 2001, BLOOD, V98, p386B